CADL Candel Therapeutics, Inc.

8-K Current Report

Filed: February 23, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Candel Therapeutics, Inc. (CADL) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Offering priced at $5.45/share for 18,348,624 firm shares; underwriters hold 30-day option for 2,752,293 additional shares
• Net proceeds ~$93.5M (or ~$107.6M if overallotment exercised fully) — meaningful cash infusion for a clinical-stage biotech

+3 more insights

Item 8.01 · Other Events

• Offering raises ~$93.5M net proceeds, extending cash runway into Q1 2028
• Underwriters hold option to purchase additional shares, potentially increasing total raise above $93.5M

+2 more insights

Other Candel Therapeutics, Inc. 8-K Filings

8-K Mar 12, 2026

Get deeper insights on Candel Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.